Immunocore Holdings plc

Equities

IMCR

US45258D1054

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-19 pm EDT 5-day change 1st Jan Change
55.68 USD +1.72% Intraday chart for Immunocore Holdings plc -1.50% -18.50%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Immunocore Holdings Files Mixed-Securities Shelf Registration MT
Transcript : Immunocore Holdings plc Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:30 AM
Mizuho Securities Raises Immunocore Price Target to $90 From $86, Maintains Buy Rating MT
Oppenheimer Adjusts Immunocore Price Target to $87 From $85, Maintains Outperform Rating MT
Immunocore Holdings' Q4 Net Loss Narrows, Revenue Rises MT
Transcript : Immunocore Holdings plc, Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (IMCR) IMMUNOCORE HOLDINGS LIMITED Reports Q4 Revenue $70.2M, vs. Street Est of $68.5M MT
Immunocore Holdings plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Immunocore Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Immunocore Collaborates With Bristol Myers Squibb in Advanced Cutaneous Melanoma Trial MT
Mizuho Raises Price Target on Immunocore to $86 From $72 Ahead of Q4 2023 Earnings Announcement, Reiterates Buy Rating MT
Immunocore Prices Upsized $350 Million Convertible Notes Offering MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday MT
Immunocore Plans $300 Million Convertible Senior Notes Offering ; Shares Fall After-Hours MT
Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023 CI
Transcript : Immunocore Holdings plc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:00 AM
Immunocore Holdings Insider Sold Shares Worth $305,781, According to a Recent SEC Filing MT
Immunocore Plans to Boost Sales, Expand Access to Kimmtrak in 2024 MT
Immunocore Holdings plc Announces the Addition of Two New Pre-Clinical Candidates for Autoimmune Diseases to Its Pipeline CI
Mizuho Cuts Price Target on Immunocore to $72 From $74, Reiterates Buy Rating MT
Immunocore Holdings plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cantor Fitzgerald Initiates Coverage on Immunocore with Overweight Rating MT
Baird Initiates Immunocore With Outperform Rating, Price Target is $84 MT
Immunocore Says Metastatic Uveal Melanoma Therapy Showed Long-Term Survival Benefit in Late-Stage Trial MT
Oppenheimer Adjusts Immunocore Price Target to $85 From $75, Maintains Outperform Rating MT
Chart Immunocore Holdings plc
More charts
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
44.85 GBP
Average target price
66.67 GBP
Spread / Average Target
+48.65%
Consensus
  1. Stock Market
  2. Equities
  3. IMCR Stock
  4. News Immunocore Holdings plc
  5. Immunocore Collaborates With Bristol Myers Squibb in Advanced Cutaneous Melanoma Trial